Ribonexus is a biopharmaceutical startup that focuses on developing innovative therapies to combat drug resistance in cancer cells. The company's work is based on the research and technology from three prestigious French research institutes - Gustav Roussy, Institut Curie, and University of Strasburg - and Pierre Fabre, a renowned pharmaceutical company.

The company's primary mission is to overcome chemoresistance, a common problem where cancer cells become resistant to chemotherapy drugs, and restore sensitivity to targeted therapies. In simpler terms, Ribonexus is working on making cancer treatments more effective by ensuring that the drugs used can successfully kill cancer cells without the cells developing resistance to them.

Ribonexus operates in the biopharmaceutical market, a sector that focuses on the discovery, development, and production of drugs based on biological molecules. The company's business model is centered on research and development, with the aim of creating new therapies that can be licensed or sold to larger pharmaceutical companies or healthcare providers.

The company is financially backed by investors who have a proven track record in the biopharmaceutical sector. The team leading Ribonexus is composed of industry veterans and advisors with extensive experience in the discovery and development of both small molecules and biological therapeutic products in oncology and other disease fields.

In conclusion, Ribonexus is a promising startup with a noble mission of improving cancer treatment effectiveness. Its innovative approach to overcoming drug resistance in cancer cells could potentially save and extend many lives.

Keywords: Biopharmaceutical, Cancer Treatment, Drug Resistance, Chemoresistance, Research and Development, Oncology, Therapeutic Products, Small Molecules, Biological Molecules, Investors.